- The primary efficacy analysis demonstrated that BNT162b2 is 95% effective against COVID-19 beginning 28 days after the first dose. The study evaluated 170 confirmed cases of COVID-19 with 162 in PBO group vs 8 in the vaccine group
- The observed efficacy in adults over 65yrs. of age was ~94% and was well tolerated across all populations with ~43,000 participants, no serious safety concerns were observed
- The companies plan to submit the data within days to the FDA for EUA and share data with other regulatory agencies across the globe and expect to produce globally ~50M vaccine doses in 2020 and ~1.3B doses by the end of 2021
Click here to read full press release/ article | Ref: Businesswire | Image: Pfizer
The post Pfizer and BioNTech’s BNT162b2 Demonstrates 95% Efficacy in Preventing COVID-19 first appeared on PharmaShots.